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Abstract 
The serotonin 5-HT2A and glutamate mGlu2 receptors continue to attract particular attention 
given their implication in psychosis associated with schizophrenia and the mechanism of 
action of atypical antipsychotics and a new class of antipsychotics, respectively. A large 
body of evidence indicates a functional crosstalk between both receptors in the brain, but the 
underlying mechanisms are not entirely elucidated. Here, we have explored the influence of 
5-HT2A receptor upon the phosphorylation pattern of mGlu2 receptor in light of the 
importance of specific phosphorylation events in regulating G protein-coupled receptor 
signaling and physiological outcomes. Among the five mGlu2 receptor phosphorylated 
residues identified in HEK-293 cells, the phosphorylation of Ser843 was enhanced upon 
mGlu2 receptor stimulation by the orthosteric agonist LY379268 only in cells co-expressing 
the 5-HT2A receptor. Likewise, administration of LY379268 increased mGlu2 receptor 
phosphorylation at Ser843 in prefrontal cortex of wild type mice but not 5-HT2A-/- mice. 
Exposure of HEK-293 cells co-expressing mGlu2 and 5-HT2A receptors to 5-HT also 
increased Ser843 phosphorylation state to a magnitude similar to that measured in 
LY379268-treated cells. In both HEK-293 cells and prefrontal cortex, Ser843 phosphorylation 
elicited by 5-HT2A receptor stimulation was prevented by the mGlu2 receptor antagonist 
LY341495, while the LY379268-induced effect was abolished by the 5-HT2A receptor 
antagonist M100907. Mutation of Ser843 into alanine strongly reduced Gi/o signaling elicited 
by mGlu2 or 5-HT2A receptor stimulation in cells co-expressing both receptors. Collectively, 
these findings identify mGlu2 receptor phosphorylation at Ser843 as a key molecular event 
that underlies the functional crosstalk between both receptors.  
- 2 - 
Introduction 
Amongst the 14 5-hydroxytryptamine (serotonin, 5-HT) receptor subtypes, the 5-HT2A 
receptor still raises special interest given its role in the psychotropic effects of psychedelic 
hallucinogens, which are often used to probe the psychosis associated with schizophrenia, 
and in the therapeutic effects of atypical antipsychotics like clozapine, olanzapine and 
risperidone, which act as antagonists or inverse agonists of the receptor (1,2). Atypical 
antipsychotics are efficient against positive symptoms of schizophrenia (hallucinations, 
delusions and disorder of thought), but they poorly control negative symptoms (social 
isolation, anhedonia and inactivity) and are often not efficient against cognitive symptoms 
(poor "executive functioning", lack of attention, impaired working memory) (3). During the 
90ies, a new class of antipsychotics acting as orthosteric agonists (LY354740, LY379268, 
LY404039) or positive allosteric modulators (PAMs, LY487379, BINA) of group II 
metabotropic glutamate receptors (mGlu2/3) has been developed. Subsequent preclinical 
studies indicated that mGlu2 receptor activation accounts for their antipsychotic activity (4–6) 
and showed overall superiority over 5-HT2A receptor antagonists in alleviating negative 
symptoms. Furthermore, an integrated study combining five placebo-controlled trials of 
pomaglumetad, the oral prodrug of LY404039, demonstrated clinical efficacy of glutamate-
based pharmacotherapy in schizophrenia in specific patient subgroups, such as patients at 
early disease stage and, interestingly, patients who had never been treated with 5-HT2A 
receptor antagonists (7).  
5-HT2A and mGlu2 receptors are canonically coupled to Gq and Gi/o proteins, respectively, 
and thus induce different signaling cascades, but they do not function as independent 
targets of antipsychotics. Electrophysiological and behavioral studies have demonstrated a 
functional antagonism between 5-HT2A and mGlu2 receptors: pharmacological activation of 
mGlu2 receptor inhibits glutamate release and excitatory postsynaptic currents (EPSCs) 
elicited by 5-HT2A receptor stimulation in the prefrontal cortex, and attenuates behavioral 
effects of hallucinogens, while mGlu2 receptor antagonists further enhance the frequency 
and amplitude of 5-HT2A receptor-induced EPSCs (7, 8). It has recently been proposed that 
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the functional crosstalk between both receptors does not solely occur at the level of neuronal 
networks or intracellular signaling cascades, but that it involves the formation of 5-HT2A-
mGlu2 heteromers, which integrate inputs from ligands of each protomer to trigger unique 
signaling and behavioral outcomes (9). In vitro and in vivo data identified the 5-HT2A-mGlu2 
heterocomplex as a possible target of hallucinogenic 5-HT2A receptor agonists that mediates 
engagement of Gi/o signaling and the associated psychotropic effects (9). Conversely, 5-
HT2A-mGlu2 heteromers are necessary for the stimulation of Gq signaling by mGlu2 receptor 
agonists, which is altered in patients with schizophrenia (10). This particular signaling also 
depends on the ability of mGlu2 receptor to couple to and activate Gi/o proteins (10). Finally, 
studies showed that 5-HT2A-mGlu2 heteromers serve as an integration point that determines 
the balance between Gi/o and Gq-dependent signaling, and pro-psychotic (increase in Gq vs. 
Gi/o signaling) vs. antipsychotic (increase in Gi/o vs. Gq signaling) outcome (11). These 
findings pinpoint the role of 5-HT2A-mGlu2 heteromers in the homeostatic equilibrium 
between Gi/o and in Gq signaling that ensures a normal non-psychotic state. However, the 
existence of 5-HT2A-mGlu2 heteromers and their physiological relevance still remain 
controversial in absence of unequivocal demonstration of the co-localization of both 
receptors in neurons (12). There is even predominant evidence for a presynaptic localization 
of mGlu2 receptors while 5-HT2A receptors are mainly localized at the post-synapse (12).  
Given the importance of specific phosphorylation events in determining the signaling and 
physiological outcomes of G protein-coupled receptors (GPCRs) (13), phosphorylation of 5-
HT2A and mGlu2 receptors is another mechanism that might contribute to the functional 
crosstalk between both receptors, irrespective of heteromer formation. In a previous study, 
we extensively characterized 5-HT2A receptor phosphorylated sites and identified a serine 
residue in the third receptor intracellular loop (Ser280) phosphorylated in response to receptor 
activation by hallucinogenic 5-HT2A receptor agonists, such as lysergic acid diethylamide 
(LSD) or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), but not by non-
hallucinogenic agonists, such as lisuride or ergotamine (14). This study also showed that the 
phosphorylation of Ser280 underlies the lower propensity of hallucinogens to induce receptor 
- 4 - 
desensitization and internalization, compared with non-hallucinogenic agonists (14). These 
data suggest that biased phosphorylation of 5-HT2A receptor by hallucinogenic vs. non-
hallucinogenic agonists might account for their distinct behavioural outcomes upon long-term 
treatment. Using an in vitro phosphorylation assay, another study also identified several 
residues phosphorylated in the mGlu2 receptor C-terminal domain and showed that the 
phosphorylation of one of them (Ser843) by protein kinase A (PKA) affects receptor coupling 
to G proteins (15). However, the reciprocal influence of 5-HT2A and mGlu2 receptors on their 
phosphorylation state and the role of their phosphorylation in the functional crosstalk 
between both receptors remain unexplored.  
Here, we characterized phosphorylated residues of mGlu2 receptor expressed in HEK-293 
cells and investigated the influence of 5-HT2A receptor expression/stimulation upon their 
phosphorylation state using high-resolution mass spectrometry. Among the identified 
residues, we show that Ser843 phosphorylation elicited by agonist stimulation of mGlu2 
receptor depends on 5-HT2A receptor co-expression and demonstrate a reciprocal interplay 
between the activation of both receptors to promote Ser843 phosphorylation. Characterization 
of the signaling outcome of Ser843 phosphorylation revealed its key role in Gi/o signaling 
elicited by 5-HT2A and mGlu2 receptors agonists in cells co-expressing both receptors. 
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Materials and Methods 
Materials 
Human Embryonic Kidney-293 (HEK-293) N type cells (RRID:CVCL_0045) were from the 
American Type Culture Collection (Anassas, VI, ATCC, CRL-1573). All experiments of the 
study were performed using a previously characterized batch of cells (Isolate #3) (16). Their 
negative mycoplasma status was analyzed every month using the MycoAlert Mycoplasma 
Detection Kit (Lonza, Switzerland). Culture media were from Invitrogen. M100907 maleate 
was a generous gift from Dr Jean-Michel Rivet (Institut de Recherches Servier, Croissy-sur-
Seine, France). LY379268 (mGlu2 receptor orthosteric agonist), LY341495 (mGlu2 receptor 
antagonist), KT5720 (PKA inhibitor) and D4476 (casein kinase 1 inhibitor) were from Tocris, 
lisuride maleate from Santa Cruz Biotechnologies, 5-HT and DOI from Sigma Aldrich. 
Pertussis Toxin (PTX) was from Calbiochem® and FR900359 was produced as previously 
described (17). 
The rat anti-Hemagglutinin (HA) antibody (11867423001) was from Roche, the rabbit anti-
Flag antibody (F7425) and the mouse anti-Flag M2 antibody conjugated to magnetic beads 
(M8823) were from Sigma Aldrich. The rabbit anti-CK1ε (#12448) was from Cell Signaling 
and the mouse anti-Actin (#MA5-11869) was from ThermoScientific. The anti-phospho-
Ser843 antibody was generated by immunizing rabbits with the synthetic CAAPRAsANLGQG 
peptide coupled to KLH (Eurogentec®). Antibodies were purified by two consecutive affinity 
chromatographies. A first chromatography against the immobilized phosphorylated 
CAAPRAsANLGQG peptide as bait bound antibodies recognizing both phosphorylated and 
unphosphorylated forms of the peptide. The retained fraction was then eluted and used for a 
second chromatography against the immobilized non-phosphorylated CAAPRASANLGQG 
peptide. We considered that the non-retained fraction of the second chromatography step 
contains antibodies recognizing mGlu2 receptor phosphorylated at Ser843. 
The PRK5 plasmid encoding the HA-tagged 5-HT2A receptor was described elsewhere (18). 
The cDNA encoding HA-tagged 5-HT2A(D120N) was generated by site-directed mutagenesis 
from this plasmid. The pcDNA3 plasmids encoding the Flag-tagged human and rat mGlu2 
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receptors were generously provided by Dr. Philippe Rondard (Institut de Génomique 
Fonctionnelle, Montpellier, France). The cDNAs encoding human and rat S843A mGlu2 
receptors and human S843D and S844A mGlu2 receptor were obtained by gene synthesis 
(Eurogentec®) and subcloned in pcDNA3. The pcDNA3 plasmid encoding human CaV2.2 
calcium channel isoform and the single dual promotor plasmid (pDuo) encoding rat Cavα2-
δ1-b and Cavβ1b ancillary subunits cloned in a single dual promotor plasmid (pDuo) were 
described elsewhere (19). The peGFPC1 plasmid was from Clontech. 
Cell cultures and transfection 
HEK-293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) + GlutaMAX 
(Life Technologies) supplemented with 10% dialyzed, heat-inactivated fetal calf serum 
(BioWhittaker) and antibiotics in a humidified 5% CO2 incubator at 37°C. They were 
transfected at 40-50% confluence using polyethyleneimine (PEI, Sigma-Aldrich), as 
previously described (20), and used 48 h after transfection. CKIε siRNA (FlexiTube siRNA 
CKIε; Cat.N° SI00287735 / SI00287728 / SI04434843 / SI04434836) and control siRNA 
(AllStars Negative Control siRNA; Cat.N° 107280) were purchased from QIAGEN. siRNA 
transfection in HEK-293 cells (at 40-50% confluence) was performed with Lipofectamine® 
2000 (Invitrogen) according to the manufacturer’s protocol using a final siRNA concentration 
of 10 nM. Cells were used 48 h after transfection. 
Quantitative mass spectrometry analysis of mGlu2 receptor phosphorylation  
Transfected cells were starved of serum for 4 h, challenged with either vehicle or LY379268 
(1  μM) for 15 min and lysed in Triton X-100 (2%), sodium chloride (150 mM), Tris-HCl (50 
mM, pH 7.5), EDTA (2 mM), EGTA (2 mM), SDS (0.2%), sodium orthovanadate (1 mM), 
sodium fluoride (50 mM), sodium β-glycerophosphate (25 mM), sodium pyrophosphate (5 
mM) and a protease inhibitor cocktail (Roche). The samples were incubated under rotation 
for 1 h at 4°C and centrifuged for 15 min at 16,000 x g to eliminate insoluble material. Flag-
tagged mGlu2 receptor was immunoprecipitated from 10 mg protein extracts using the anti-
Flag M2 antibody immobilized on magnetic beads. After reduction with dithiothreitol (10 mM, 
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10 min at 37˚C) and alkylation with iodoacetamide (50 mM, 45 min at 25˚C), 
immunoprecipitated mGlu2 receptors were resolved by SDS-PAGE and digested in-gel with 
trypsin (10 ng/mL, Gold, Promega) or with chymotrypsin (10 ng/mL, Gold, Promega) 
overnight at 25˚C. Peptides were analyzed by nano-flow liquid chromatography coupled to 
Fourier transform tandem mass spectrometry (nanoLC-FT-MS/MS) using a LTQ Velos Pro 
Orbitrap Elite mass spectrometer coupled to an Ultimate 3000 (Thermo Fisher Scientific). 
Desalting and pre-concentration of samples were performed on-line on a Pepmap precolumn 
(0.3 mm 10 mm, Dionex) in buffer A (2% acetonitrile, 0.1% formic acid). A gradient 
consisting of 2–40% buffer B (B = 99.9% acetonitrile with 0.1% formic acid) (3–33 min), 40–
80% B (33–34 min), 80–0% B (49–50 min), and equilibrated for 20 min in 0% B (50–70 min) 
was used to elute peptides at 300 nL/min from a Pepmap capillary reversed-phase column 
(0.075 mm x 150 mm, Thermo Fisher Scientific). Mass spectra were acquired using a top-10 
collision-induced dissociation (CID) data-dependent acquisition (DDA) method. The LTQ-
Orbitrap was programmed to perform a FT full scan (60,000 resolution) on 400–1,400 Th 
mass range with the top ten ions from each scan selected for LTQ-MS/MS with multistage 
activation on the neutral loss of 24.49, 32.66 and 48.99 Th. FT spectra were internally 
calibrated using a single lock mass (445.1200 Th). Target ion numbers were 500,000 for FT 
full scan on the Orbitrap and 10,000 MSn on the LTQ. Precursor mass and top 6 per 30 Da 
windows peak lists were extracted from MS2 using MSconvert 3.0 and searched with Mascot 
2.6 against the human or rat Complete Proteome Set database (http://www.uniprot.org), 
cysteine carbamidomethylation as a fixed modification and phosphorylation of Ser, Thr and 
Tyr as variable modifications, 7 ppm precursor mass tolerance, 0.5 Da fragment mass 
tolerance and trypsin/P or chymotrypsin digestion. MS2 spectra matching phosphorylated 
peptides with ion score over 15 were manually inspected for unique transitions that pinpoint 
the position of phosphorylation sites. Ion signals corresponding to phosphorylated peptides 
were quantified from the maximal intensities measured in their ion chromatograms manually 
extracted using Qual browser v2.1 (Thermo Fisher Scientific) with a tolerance of 5 ppm for 
mass deviation, and normalized to signals of their non-phosphorylated counterparts. For 
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each identified phosphorylated residue, a phosphorylation index [phosphorylated peptide ion 
signal intensity / (phosphorylated peptide ion signal intensity + non-phosphorylated peptide 
ion signal intensity)], was calculated. 
Western Blotting 
Proteins, resolved onto 10% polyacrylamide gels, were transferred electrophoretically to 
nitrocellulose membranes (Biorad). Membranes were immunoblotted with primary antibodies 
(anti phospho-Ser843 mGlu2 receptor, 1:2,000; anti-Flag, 1:1,000; Anti-HA, 1:1,000) and then 
with either anti-rat (Jackson ImmunoResearch 112-035-003) or anti-rabbit (Sigma Aldrich 
GENA934V) or anti-mouse (Sigma Aldrich GENA931V) horseradish peroxidase (HRP)-
conjugated secondary antibodies (1:5,000). Immunoreactivity was detected with an 
enhanced chemiluminescence method (Western lightning® Plus-ECL, Perkin Elmer) on a 
ChemiDocTm Touch Imaging System (Biorad). Immunoreactive bands were quantified by 
densitometry using the ImageJ software (v.1.50). In protein phosphorylation analyses, the 
amount of each phosphoprotein was normalized to the amount of the corresponding total 
protein detected in the sample. 
Analysis of Ser843 phosphorylation in the mouse prefrontal cortex 
Experiments on mice (C57/Bl6J, eight weeks old, male) conformed to European ethics 
standards (86/609-EEC) and to decrees of the French National Ethics Committee (N°87/848) 
for the care and use of laboratory animals. Protocols were approved by regional ethic 
committee for animal use (CEEA LR 34, #7251). A minimum of four animals was used for 
each group. Animals were randomly allocated into the different groups by an observer who 
was blind to the experimental conditions. Prior to immunochemistry, brains were randomly 
numbered in order to perform immunochemistry and image acquisition in a blind way and 
reassign the samples to their group afterwards. Mice (about 20 g) were injected i.p. with 
either vehicle (5% DMSO/5% Tween-80) or LY379268 (10 mg/kg) or DOI (10 mg/kg) or 
lisuride (10 mg/kg). M100907 (5 mg/kg) or LY341495 (3 mg/kg) were injected 15 min prior to 
vehicle or agonists. LY379268 was also administered to 5-HT2A-/- (21) and mGlu2-/- (22) mice 
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(originally provided by Prof. Shigetada Nakanishi at Kyoto University, Japan), and DOI to 
mGlu2-/- mice. Thirty min after agonist injection, mice were anesthetized with pentobarbital 
(100 mg/kg i.p., Ceva SA) and perfused transcardiacally with fixative solution containing 4% 
w/v paraformaldehyde, 0.1 M sodium phosphate buffer (pH 7.5), sodium fluoride (10 mM) 
and sodium orthovanadate (2 mM). Brains were post-fixed for 48 h in the same solution and 
stored at 4°C. Thirty µm-thick sections were cut with a vibratome (Leica). Sections were 
incubated with a solution containing 0.2% Triton X-100, 3% bovine serum albumin (BSA) 
and 2% goat serum in Tris buffer saline (TBS) for 30 min. They were then incubated for 24 h 
at 4°C with the anti-phospho-Ser843 antibody (1:500) in TBS containing 3% BSA. After four 
washes, they were incubated for 1 h with an Alexa Fluor® 488-conjugated anti-rabbit 
antibody (1:2,000, Invitrogen) in TBS containing 2.5% BSA and 0.08% Triton X-100. 
Immunofluorescent staining was observed with a Zeiss Axioimager Z1 microscope equipped 
with apotome (Carl Zeiss). Images were acquired using the Zen2 (blue edition) software 
driving an AxioCam MRm CCD camera (Carl Zeiss). Image analysis was performed with the 
Image J software (v1.50) and results were expressed in percentage of anti-phospho-Ser843-
positive cells relative to DAPI-stained cells. 
 
ELISA 
Quantification of cell surface expression of HA-tagged 5-HT2A receptors and Flag-tagged 
wild-type, S843A and S843D mGlu2 receptors was performed by ELISA under non-
permeabilized conditions, as previously described (23). Dilutions for primary antibodies were 
1:400 (Anti-HA) and 1:1,000 (anti-Flag). Secondary antibodies (donkey anti-mouse or anti-
rabbit conjugated to HRP, GE Healthcare) were used at 1:5,000 dilution. Immunoreactive 
signal was detected with a M200 Infinite plate reader (Tecan), using the SuperSignal ELISA 
Femto chromogenic substrate (Thermo Scientific). Control experiments were performed 
using cells transfected with empty vectors. 
Electrophysiology 
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HEK-293 cells were co-transfected with plasmids encoding Flag-tagged wild-type or S843A or 
S843D mGlu2 receptor, HA-tagged 5-HT2A receptor, Cav2.2, Cavβ1b and Cavα2-δ1-b ancillary 
subunits and GFP (to detection of transfected cells). Twenty-four hours after transfection, 
cells were dissociated with Versene (Invitrogen), and plated at low density in poly-ornithine-
coated 35-mm Petri dishes for 24 h. Cells were incubated with extracellular solution 
containing 125 mM NaCl, 20 mM TEACl, 10 mM HEPES, 5mM BaCl2, 1 mM MgCl2 and pH 
was adjusted to 7.3 with TEAOH. Borosilicate glass pipettes (2–4 MΩ, Sutter instrument) 
were filled with internal solution containing 130 mM CsCl, 10 mM HEPES, 10 mM EGTA, 2 
mM CaCl2, 1 mM MgCl2, 4 mM MgATP, 0.3 mM Tris-GTP (pH adjusted to 7.3 with NaOH). 
Currents were elicited from a holding potential of -80 mV to 0 mV during 10 msec repeated 
each 1 sec. Data were plotted as means ± SEM. Statistical difference (p < 0.05) was 
determined using one-way analysis of variance. 
 
Statistics 
Statistical analyses were performed using Prism (v. 7.0, GraphPad Software Inc.). 
Histograms show means ± SEMs. One-way ANOVA followed by Tukey’s and Dunnett’s tests 
were performed for multiple comparisons to multiple groups or to a single group, 
respectively. For each statistical test, F value was calculated in order to determine how the 
variance between the mean values obtained in different populations is significantly different. 
F value, number of independent biological replicates and sample size (or number of animals 
per condition) are indicated in the corresponding figure legends. MS peptide identification 
probabilities were calculated using the Mascot algorithm. Mascot score represents -
10*LOG10(p-value), where p-value is the absolute probability of peptide wrong assignment. 
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Results 
Agonist-stimulated mGlu2 receptor phosphorylation at Ser843 requires co-expression 
of 5-HT2A receptor in HEK-293 cells 
To identify novel molecular substrates of the functional crosstalk between 5-HT2A and mGlu2 
receptors, we first examined the phosphorylation pattern of Flag-tagged human mGlu2 
receptor co-expressed with HA-tagged 5-HT2A receptor in HEK-293 cells following exposure 
to vehicle or a maximally-effective concentration of the mGlu2 receptor orthosteric agonist 
LY379268 (1 µM) (24). mGlu2 receptors were purified by immunoprecipitation followed by 
SDS-PAGE. They were then digested in-gel with trypsin. Analysis of peptides from vehicle or 
LY379268-treated cells by nano-flow liquid chromatography coupled to high-resolution 
tandem mass spectrometry (nano-LC-MS/MS) yielded 57 % coverage of the entire receptor 
sequence and 75% coverage of intracellular domains, with a p-value threshold of 0.05 for 
peptide identification (Supplementary Figure1). LC-MS/MS analysis identified one 
phosphorylated residue located in the third extracellular domain of the receptor (Thr718) and 
four residues in the C-terminal domain (Ser833, Ser837, Ser843/844 and Ser871, Table 1, Figure 
1A, Supplementary Figures 2-5). Note that MS/MS fragmentation did not discriminate 
between a phosphorylation at Ser843 or Ser844, due to the absence of site-specific fragment 
ions in MS/MS spectra (Supplementary Figure 4). In an effort to distinguish Ser843 from 
Ser844 phosphorylation, purified mGlu2 receptor was digested with chymotrypsin to generate 
a proteolytic peptide with the two serine residues located in the central part of the sequence, 
which should be enriched in discriminant fragment ions. Unfortunately, chymotrypsin 
digestion yielded only 31 % receptor sequence coverage (Supplementary Figure 6A) and the 
two theoretically discriminant ions were not detected in the corresponding fragmentation 
spectra (Supplementary Figure 6B). 
Alignment of human, mouse and rat mGlu2 receptor sequences revealed that the region 
encompassing Ser843 and Ser844 is highly conserved in the three species (Figure 1B). 
Specifically, Ser843 of the human receptor is conserved in rat and mouse orthologs, whereas 
Ser844 is replaced by an alanine (Figure 1B). We thus renewed the experiments in cells 
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expressing the rat mGlu2 receptor and clearly identified a peptide phosphorylated at Ser843 
(Supplementary Figure 7). Consistent with these findings, a peptide comprising 
phosphorylated Ser843 was likewise identified in cells expressing the S844A mutant of the 
human mGlu2 receptor (Supplementary Figure 8), while no peptide phosphorylated at Ser844 
was detected in cells expressing the S843A mutant. Collectively, these results unambiguously 
identify Ser843 as the phosphorylated residue in the human and murine receptors. 
To explore the impact of agonist stimulation of mGlu2 receptor and 5-HT2A receptor 
expression upon mGlu2 receptor phosphorylation, we next compared the phosphorylation 
index of each identified phosphorylated residue in cells exposed or not to LY379268, in the 
presence or absence of 5-HT2A receptor. The phosphorylation index of Thr718, Ser833, Ser837 
and Ser871 did not display any significant variation upon exposure of cells to LY379268 or co-
expression of 5-HT2A receptor (Table 1 and Supplementary Figures 2B, 3B, 5B). In contrast, 
LY379268 induced a marked increase in Ser843 phosphorylation in cells co-expressing 
human mGlu2 and 5-HT2A receptors while it did not significantly affect its phosphorylation 
state in cells expressing mGlu2 receptor alone (Figure 1C). Likewise, LY379268 exposure of 
cells expressing the rat mGlu2 receptor increased Ser843 phosphorylation only when the 5-
HT2A receptor was co-expressed (Figure 1C and Supplementary Figure 7). Collectively, 
these findings demonstrate that agonist stimulation of mGlu2 receptor induces the 
phosphorylation of a conserved serine residue in human and murine receptors in HEK-293 
cells, an effect dependent of the presence of 5-HT2A receptor. 
 
Agonist-stimulated mGlu2 receptor phosphorylation at Ser843 in the mouse prefrontal 
cortex requires co-expression of 5-HT2A receptor  
A polyclonal antibody against the mGlu2 receptor phosphorylated at Ser843 was obtained by 
immunizing a rabbit with the synthetic CAAPRAsANLGQG peptide encompassing a 
phosphorylated serine residue corresponding to Ser843 in the entire murine receptor. We 
checked the specificity of the antibody for the phosphorylated site by immunoblotting on 
HEK-293 cell protein extracts. No immunoreactive signal was observed in blots from cells 
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transfected with empty vector, but a clear signal was detected at the expected molecular 
weight in blots obtained from cells expressing the rat mGlu2 receptor (Supplementary Figure 
9). Furthermore, LY379268 treatment strongly enhanced this immunoreactive signal only in 
cells co-expressing the 5-HT2A receptor, consistent with the results of MS analysis (Figure 
1C and Supplementary Figure 9). Mutation of Ser843 into alanine abolished this 
immunoreactive signal, confirming the specificity of the antibody for phosphorylated Ser843 
(Supplementary Figure 9). The maximal signal intensity was reached at LY379268 
concentration as low as 1 nM (Supplementary Figure 10A). Notably, expression of 5-HT2A 
receptor at various densities (in absence of LY379268) did not enhance phosphorylation of 
Ser843 of mGlu2 receptor (Supplementary Figure 11). As expected, the increase in Ser843 
phosphorylation induced by LY379268 was prevented by the co-application of the mGlu2 
receptor antagonist LY341495 (10 µM, Supplementary Figure 12). An increase in the anti-
phospho-Ser843 antibody immunoreactivity was also observed in Western blots from cells 
expressing the human mGlu2 receptor, though the intensity of the immunoreactive signal 
was much lower than that measured in cells expressing the rat receptor (Supplementary 
Figure 13), suggesting a higher affinity of our anti-phospho-Ser843 antibody for the murine 
phosphorylated receptor.  
We next took advantage of this antibody to investigate the phosphorylation of native mGlu2 
receptor in the mouse prefrontal cortex, a brain region where mGlu2/5-HT2A heteromers have 
been identified (9). We injected mice with either vehicle of LY379268 (10 mg/kg, 30 min) and 
assessed mGlu2 phosphorylation by immunohistochemisty. Reminiscent of the data obtained 
in HEK-293 cells, LY379268 administration strongly increased immunostaining with the anti-
phospho-Ser843 antibody (Figure 1D). The most intense signal was observed in middle layers 
of prefrontal cortex, which express the highest density of 5-HT2A receptor (25). As observed 
in HEK-293 cells, Ser843 phosphorylation elicited in mouse prefrontal cortex by injecting 
LY379268 was also prevented by the administration of LY341495, which alone did not affect 
Ser843 phosphorylation (Figure 1D). Confirming the specificity of our antibody for 
phosphorylated mGlu2, no signal was detected in prefrontal cortex of mGlu2 receptor 
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knockout (mGlu2-/-) mice treated with either vehicle or LY379268 (Figure 1D). Moreover, 
administration of LY379268 to 5-HT2A receptor knockout (5-HT2A-/-) mice did not increase the 
phospho-Ser843 immunoreactive signal in prefrontal cortex (Figure 1D), indicating that 5-HT2A 
receptor expression is also necessary for LY379268-induced phosphorylation of native 
mGlu2 receptor at Ser843. 
Ser843 phosphorylation is mediated by casein kinase 1 (CK1)  
In order to identify protein kinase(s) involved in Ser843 phosphorylation, mGlu2 receptor 
sequence surrounding Ser843 was uploaded into Group-based Prediction System (GPS©, 
v3.0), a software for kinase consensus search that ranks protein kinases into a hierarchical 
tree with four levels and builds its algorithm against the PhosphoELM database, in order to 
calculate false discovery rates for each of them (26). GPS search revealed that Ser843 is a 
good consensus for phosphorylation by casein kinase 1 (CK1, GPS© score 9.3), and cyclic 
AMP-dependent protein kinase (PKA, GPS© score 4.1), consistent with previous findings 
(15). Pretreatment of HEK-293 cells co-expressing mGlu2 and 5-HT2A receptor with the CK1 
inhibitor D4476 (10 µM, 60 min) (27) abolished LY379268-induced phosphorylation of Ser843, 
whereas the PKA pharmacological inhibitor KT5720 (1 µM, 60 min) (28) did not affect the 
level of Ser843 phosphorylation (Figure 2A), suggesting that CK1 rather than PKA promotes 
Ser843 phosphorylation in living cells. Treatment of cells with D4476 did not affect the low 
Ser843 phosphorylation level measured in cells expressing mGlu2 receptor alone and 
challenged with LY379268 (Supplementary Figure 14).  
Among the CK1 isoforms, GPS search pointed CK1δ and CK1ε as the best candidates able 
to phosphorylate Ser843. Given the high CK1ε expression level and the very low expression 
of CK1δ in prefrontal cortex (http://mouse.brain-map.org/), we targeted specifically the ε 
isoform using RNA interference. Silencing CK1ε expression abolished LY379268-induced 
Ser843 phosphorylation in cells co-expressing 5-HT2A receptor (Figure 2B and Supplementary 
Figure 15), reminiscent of the effect of cell exposure to D4476 (Figure 2A). 
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Gi/o and Gq proteins are involved in Ser843 phosphorylation elicited by mGlu2 receptor 
stimulation in cells co-expressing 5-HT2A receptor 
In line with the canonical coupling of mGlu2 and 5-HT2A receptors to Gi/o and Gq proteins, 
respectively, we next explored their influence on LY379268-induced Ser843 phosphorylation 
in cells co-expressing both receptors. LY379268 exposure did not increase Ser843 
phosphorylation in cells pretreated with the Gi/o inhibitor Pertussis toxin (PTX, 100 ng/mL, 18 
h) or the pharmacological Gq/11 inhibitor FR900359 (1 μM, 2 h) (17), indicating that the 
activation of both Gi/o and Gq/11 is necessary to LY379268-induced Ser843 phosphorylation 
(Supplementary Figure 16A). Further supporting the role of Gq/11 activation by unliganded 5-
HT2A receptor, LY379268 exposure did not promote Ser843 phosphorylation in cells 
expressing the signaling-dead 5-HT2A(D120N) receptor (Supplementary Figure 17A) (29). 
Agonist-elicited phosphorylation of mGlu2 receptor at Ser843 promotes receptor-
operated Gi/o signaling 
To determine the role of Ser843 phosphorylation in mGlu2 receptor-mediated signal 
transduction, we measured mGlu2 receptor-operated inhibition of N-type voltage-gated 
calcium channels, a read-out commonly used to study engagement of Gi/o signaling by 
GPCRs (30,31) (Figure 3A). 
As expected, LY379268 inhibited N-type calcium channel-mediated current in a 
concentration-dependent manner (pEC50 = 8.81 ± 0.16, n = 10 cells) in HEK-293 cells 
transiently expressing mGlu2 receptor (Figure 3B). No effect of LY379268 was seen in cells 
transfected with an empty vector or transiently expressing the 5-HT2A receptor alone, but co-
expression of 5-HT2A receptor with mGlu2 receptor increased the amplitude of LY379268-
induced inhibition of N-type calcium channels without affecting its apparent affinity (pEC50 = 
8.66 ± 0.07, n = 10 cells, Figure 3B). In contrast, co-expression of 5-HT2A receptor with S843A 
mGlu2 receptor mutant did not enhance the LY379268-induced inhibition of N-type calcium 
channels, while mutation of Ser843 into aspartate, to mimic permanent phosphorylation of this 
residue, had no consequence on the level of inhibition of the N-type calcium channels by 
LY379268 (Figure 3C). Furthermore, pre-treatment of cells with the CK1 inhibitor D4476 (10 
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µM), which prevented Ser843 phosphorylation, also abolished the potentiation of the 
LY379268 response elicited by 5-HT2A receptor expression in cells co-expressing wild type 
mGlu2 receptor but not in cells co-expressing S843D mGlu2 receptors (Figure 3C). D4476 
exposure did not affect the amplitude of LY379268-induced inhibition of N-type calcium 
channels in cells expressing mGlu2 receptor alone (Figure 3C). Collectively, these results 
suggest that Ser843 phosphorylation is a necessary step of the potentiation of mGlu2 
receptor-operated Gi/o signaling induced by 5-HT2A receptor expression. This potentiation 
was not due to an enhanced expression of mGlu2 receptor at the plasma membrane, as 
ELISA experiments showed that co-expression of 5-HT2A receptors did not change the cell 
surface expression of mGlu2 receptor (Supplementary Figure 18). Further supporting the 
absence of influence of Ser843 phosphorylation on mGlu2 receptor plasma membrane 
localization, wild type, S843A and S843D mGlu2 receptors exhibited similar cell surface 
expression (Supplementary Figure 18). 
5-HT2A receptor stimulation promotes phosphorylation of mGlu2 receptor at Ser843 
Exposure of HEK-293 cells co-expressing mGlu2 and 5-HT2A receptors to 5-HT increased 
Ser843 phosphorylation state in a concentration-dependent manner and to a magnitude 
similar to that measured in LY379268-treated cells (Figures 1C and 4A, Supplementary 
Figure 10B), an effect prevented by the 5-HT2A receptor antagonist M100907 (100 nM, 
Figure 4A). Reminiscent of the LY379268-induced response, the 5-HT-induced Ser843 
phosphorylation was strongly reduced in cells expressing the Gq-dead 5-HT2A(D120N) 
receptor (Supplementary Figure 17B). Likewise, the 5-HT-elicited Ser843 phosphorylation 
was abolished in cells pretreated with FR900359 but it persisted in cells pretreated with PTX 
(Supplementary Figure 16B). The hallucinogenic 5-HT2A receptor agonist DOI (10 µM) and 
the non-hallucinogenic agonist lisuride (10 µM) induced increases in Ser843 phosphorylation 
comparable to that measured in cells challenged with 5-HT (Figure 4B). Furthermore, no 
additional increase in Ser843 phosphorylation state was measured in cells exposed to both 
LY379268 and 5-HT2A receptor agonists (5-HT, DOI or lisuride, Figure 4B).  
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Corroborating results obtained in transfected HEK-293 cells, administration of DOI (10 
mg/kg, 30 min) or lisuride (10 mg/kg, 30 min) to mice induced elevations of Ser843 
phosphorylation in prefrontal cortex similar to those measured in mice injected with 
LY379268 (Figure 4C). As expected, Ser843 phosphorylation elicited by DOI injection was 
prevented by the administration of M100907, which alone did not affect Ser843 
phosphorylation (Figure 4C). Collectively, these results indicate that Ser843 phosphorylation 
can be triggered with similar efficiencies by agonist stimulation of either 5-HT2A or mGlu2 
receptors in cells co-expressing both receptor subtypes.  
Interestingly, treatment of HEK-293 cells co-expressing 5-HT2A and mGlu2 receptors with 
LY341495, which alone did not affect Ser843 phosphorylation, inhibited the 5-HT-induced 
effect (Figure 5A). Conversely, M100907 prevented the LY379268-induced increase in 
Ser843 phosphorylation, while it slightly but not significantly decreased basal Ser843 
phosphorylation (Figure 5B). mGlu2 and 5-HT2A receptor ligands induced similar regulations 
of Ser843 phosphorylation in mouse prefrontal cortex: Ser843 phosphorylation elicited by 
injecting LY379268 was prevented by the administration of M100907 and, reciprocally, the 
DOI-induced effect was prevented by the administration of LY341495 (Figure 5C). 
Collectively, these observations indicate that phosphorylation of Ser843 elicited by the 
stimulation of 5-HT2A receptor depends on the co-expression of mGlu2 receptor at active 
conformation and vice versa. 
Impact of 5-HT2A receptor activation on Gi/o-dependent signaling under the control of 
mGlu2 receptor 
Given the role of Ser843 phosphorylation in mGlu2 receptor-operated activation of Gi/o 
signaling and the critical influence of the 5-HT2A receptor upon this phosphorylation, we also 
investigated the effect of 5-HT2A receptor stimulation on Gi/o signaling by measuring the 
activity of N-type calcium channels. In cells expressing 5-HT2A receptor alone, 5-HT (1 µM) 
already induced a weak inhibition of N-type calcium channels (Figure 5D). This inhibition 
was more pronounced in cells co-expressing wild type or S843D mGlu2 receptors, but not in 
cells co-expressing S843A mGlu2 receptor (Figure 5D). Reminiscent of their influence upon 
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Ser843 phosphorylation, both LY341495 and M100907 prevented LY379268- and 5-HT-
induced inhibition of N-type calcium channels (Figure 5E). Collectively, these data suggest a 
reciprocal interplay between 5-HT2A and mGlu2 receptors in engagement of Gi/o signaling, 
which depends on Ser843 phosphorylation.   
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Discussion  
Phosphorylation of GPCRs is classically considered as a mechanism initiating receptor 
desensitization and β-arrestin-dependent receptor internalization following sustained agonist 
exposure (32). More recently, subtle modifications of GPCR phosphorylation at specific sites 
have emerged as key molecular substrates that determine the nature of GPCR-operated 
signaling, depending on the ligand (functional selectivity) or the cell type, that can be tailored 
to meet a specific physiological function (33–38). It has also been suggested that GPCR 
heteromerization can influence the phosphorylation status of the different heteromer 
constituents, which in turn modulates signaling and physiological outcome of the heteromer. 
For instance, a recent study has shown that the RF-amide peptide NPFF, by acting at NPFF2 
receptors, induces a transphosphorylation of Mu-opioid receptor within Mu/NPFF2 
heteromers, a process responsible for a loss of function of Mu receptors and contributing to 
the tolerance to morphine analgesia induced by NPFF (39). These observations highlight the 
functional and physiological impact of GPCR phosphorylation within heterocomplexes and 
underscore the potential of deciphering the phosphorylation events on each subunit of 
GPCR heteromers to elucidate the mechanism of action of psychotropic drugs. They 
provided the impetus for the present phosphoproteomics screen aimed at characterizing the 
influence of 5-HT2A receptor expression and stimulation upon mGlu2 receptor 
phosphorylation pattern.  
We identified three (Ser833, Ser843 and Ser871) out of the 12 putative phosphorylated residues 
(Ser109, Ser111, Ser246, Thr457, Ser501, Tyr734, Tyr745, Tyr749, Thr832, Ser833, Ser843 and Ser871) 
referenced in the PhosphoSitePlus database (http://www.phosphosite.org) and two 
previously not described phosphorylated sites (Ser718 and Ser837) in human mGlu2 receptor 
co-expressed with 5-HT2A receptor in HEK-293 cells challenged with a mGlu2 receptor 
agonist. The absence of manual inspection of MS/MS spectra pinpointing the 
phosphorylated sites referenced in the PhosphoSitePlus database suggests that the majority 
of the previously described sites are actually not fully validated, though one cannot rule out 
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that the difference between our results and the previously reported ones might reflect the 
distinct biological samples and experimental conditions used.  
Among the five sites identified in the present study, only the phosphorylation of a serine 
residue (Ser843) located in the receptor C-terminal domain and conserved in the human and 
rat sequences was up-regulated upon agonist receptor stimulation. Moreover, Ser843 
phosphorylation depended on the co-expression of 5-HT2A receptor. Likewise, 
phosphorylation of mGlu2 receptor at Ser843 elicited in mice prefrontal cortex by peripheral 
administration of the mGlu2 receptor agonist LY379268 (assessed by immunohistochemistry 
using a newly-generated phospho-Ser843 antibody) was not seen in 5-HT2A-/- mice. This result 
indicates that the joint influence of 5-HT2A and mGlu2 receptors upon Ser843 phosphorylation 
can be observed on both recombinant receptors and native receptors expressed in prefrontal 
cortex, a brain structure co-expressing both receptors and important for the behavioral 
responses to 5-HT2A and mGlu2 receptor ligands (9,40). Intriguingly, 5-HT2A receptor 
stimulation by 5-HT promoted Ser843 phosphorylation as efficiently as that induced by mGlu2 
receptor stimulation, reminiscent of the transphosphorylation of Mu-opioid receptor elicited 
by NPFF receptor activation (39). Moreover, Ser843 phosphorylation induced by 5-HT (or the 
synthetic 5-HT2A receptor agonist DOI) was impaired by the mGlu2 receptor antagonist 
LY341495, while the LY379268-induced effect was prevented by the 5-HT2A receptor 
antagonist M100907, thus demonstrating a positive reciprocal influence of both receptor 
activities upon mGlu2 receptor phosphorylation at Ser843 in HEK-293 cells and mice 
prefrontal cortex. Notably, the LY379268-induced Ser843 phosphorylation depends on both 
Gi/o and Gq activation, whereas the 5-HT-induced response is only Gq-dependent. 
Collectively, these findings suggest that Ser843 phosphorylation can result from two types of 
allosteric modulation exerted by different active conformations of the 5-HT2A receptor within 
heteromers: i) an allosteric modulation by unliganded (constitutively active) 5-HT2A receptor 
of agonist-stimulated mGlu2 receptor (bound to activated Gi/o protein) and ii) an allosteric 
modulation by 5-HT-stimulated 5-HT2A receptor that is independent of mGlu2 receptor 
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stimulation by its own agonist and of Gi/o protein activation. However, one cannot rule out 
that 5-HT2A receptor-dependent Ser843 phosphorylation can also be induced indirectly, via a 
5-HT2A receptor-operated Gq/11 signaling pathway. Irrespective of the mechanism underlying 
Ser843 phosphorylation, our results identify a novel functional crosstalk mechanism between 
5-HT2A and mGlu2 receptors at the receptor level. The demonstration of this crosstalk in 
mouse prefrontal cortex strongly supports the co-localization of at least a fraction of both 
receptors expressed in this brain area and, possibly, the formation of 5-HT2A-mGlu2 
heteromers in vivo. 
The difference in signal transduction elicited by hallucinogenic and non-hallucinogenic 
agonists of the 5-HT2A receptor represents one of the best characterized examples of 
functional selectivity translated into distinct behaviors (21,41). Furthermore, we previously 
showed that the two categories of 5-HT2A receptor agonists differ in their capacities to 
promote 5-HT2A receptor phosphorylation at Ser280 (14). Such a biased phosphorylation was 
not retrieved for Ser843: treatment of cells with the hallucinogenic agonist DOI and the non-
hallucinogenic agonist lisuride induced comparable increases in Ser843 phosphorylation to 
that elicited by 5-HT. It is thus unlikely that Ser843 phosphorylation underlies the distinct 
behavioral responses induced by both ligand categories. 
Among the two kinases possibly involved in Ser843 phosphorylation suggested by the GPS 
algorithm, namely CK1 and PKA, our data based on pharmacological inhibitors and CK1 
expression silencing suggest that this phosphorylation is mediated by CK1. This contrasts 
with previous findings, which demonstrated that Ser843 can be phosphorylated in vitro by 
PKA or following a treatment of cells expressing recombinant mGlu2 receptor with the 
adenylyl cyclase activator forskolin or cell-permeable cAMP analogs. Hence, CK1 rather 
than PKA seems to be involved in the more physiological context of agonist mGlu2 receptor 
stimulation in cells co-expressing 5-HT2A receptors, consistent with the canonical coupling of 
mGlu2 receptors to Gi/o proteins and their ability to inhibit rather than stimulate cAMP 
production (42). CK1 activity generally depends on its expression level or the expression of 
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regulators, which are likely not affected by acute extracellular stimuli (43,44). In light of the 
well-established formation of 5-HT2A-mGlu2 heteromers, at least in recombinant cells (9, 34), 
we hypothesize that Ser843 might be accessible for CK1 only in a mGlu2 receptor 
conformation stabilized by its association with 5-HT2A receptor and agonist stimulation of 
either mGlu2 or 5-HT2A receptor within the heterocomplex. 
Consistent with the localization of Ser843 in mGlu2 receptor C-terminal domain, a region 
important for coupling to G proteins, several lines of evidence suggest that its 
phosphorylation is an essential step in engagement of Gi/o signaling not only upon mGlu2 
receptor activation but also following 5-HT2A receptor activation in cells co-expressing both 
receptors: i) corroborating previous findings indicating that heteromeric assembly of mGlu2 
and 5-HT2A receptors enhances glutamate-elicited Gi/o signaling (11), co-expression of 5-
HT2A receptor with mGlu2 receptor enhanced LY379268-induced inhibition of N-type 
channels (used as readout of activation of Gi/o-dependent signaling) (30,31), an effect 
suppressed by mutating Ser843 into alanine; ii) reminiscent of their influence upon Ser843 
phosphorylation, the 5-HT2A receptor antagonist M100907 prevented enhancement of 
LY379268-induced inhibition of N-type channels induced by the co-expression of 5-HT2A 
receptor, while the mGlu2 receptor antagonist LY341495 blocked the 5-HT-evoked response. 
These findings thus identify Ser843 phosphorylation as a novel molecular substrate 
underlying the functional crosstalk between 5-HT2A and mGlu2 receptors, which determines 
the level of Gi/o signaling under the control of both receptors. It has been proposed that the 
balance between Gi/o and Gq-dependent signaling determines pro-psychotic vs. antipsychotic 
activity of 5-HT2A and mGlu2 receptors ligands (11). Given the critical influence of Ser843 
phosphorylation level on mGlu2 and 5-HT2A receptor-dependent Gi/o signaling, its fine-tuning 
might be an essential mechanism contributing to the homeostatic balance that ensures a 
normal non-psychotic state.  
In conclusion, the present study identifies Ser843 phosphorylation as an early molecular 
substrate of the functional crosstalk between 5-HT2A and mGlu2 receptors that determines 
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the level of Gi/o signaling under the control of both receptors, which itself might be predictive 
of antipsychotic or pro-psychotic effects of drugs targeting each receptor. Accordingly, the 
anti-phospho-Ser843 antibody developed in this study might be a relevant tool for the 
screening of potential antipsychotic drugs in preclinical models of schizophrenia. Several 
studies also reported changes in 5-HT2A and mGlu2 receptors densities in patients with 
schizophrenia, which might contribute to the pathogenicity of the disease (9,12,46). Though 
the data show some discrepancies and must be considered cautiously due to the potential 
impact of antipsychotic drug treatment on 5-HT2A receptor expression, the majority of post-
mortem studies demonstrate a decrease in cortical 5-HT2A receptor density in patients. In 
line with these findings and the strong influence of 5-HT2A receptor expression/stimulation on 
Ser843 phosphorylation, analysis of its phosphorylation status in post-mortem brain of 
patients with schizophrenia might be of great interest. 
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Figure legends 
Figure 1. Agonist-stimulated mGlu2 receptor phosphorylation at Ser843 requires co-
expression of 5-HT2A receptor in HEK-293 cells and mouse prefrontal cortex. A, 
Schematic overview of the position of phosphorylated residues identified by MS/MS in 
human mGlu2 receptor. B, Sequence alignment of the receptor region containing Ser843 in 
human, mouse and rat mGlu2 orthologs. Note that Ser843 is conserved in the three orthologs, 
while Ser844 in the human receptor is replaced by an alanine in murine orthologs. The 
sequences in bold correspond to peptides identified by MS/MS. C, HEK-293 cells transiently 
expressing human or rat mGlu2 receptor in the absence or presence of 5-HT2A receptor were 
exposed to vehicle or LY379268 (LY37, 1 µM) for 15 min. The histograms represent the 
means ± SEM of ion signal intensities (expressed in % of signal intensity measured in cells 
co-expressing mGlu2 and 5-HT2A receptors and treated with LY379268) measured in three 
replicates. One-way ANOVA (Post-hoc: Tukey’s range test): F(3,12)=14.91, p=0.0002 and 
F(3,8)=5.558, p=0.0234, in cells expressing human and rat mGlu2, respectively. *p<0.05; 
**p<0.01; ***p<0.001. D, Wild type, 5-HT2A-/- and mGlu2-/- mice were injected with either 
vehicle or LY379268 (10 mg/kg, i.p) for 30 min. LY341495 (3 mg/kg i.p.) was injected 15 min 
before vehicle/LY379268 administration. Representative images showing phospho-Ser843-
mGlu2 immunofluorescent staining in prefrontal cortex are illustrated. The histogram shows 
the mean ± SEM of values (expressed in % of anti-phospho-Ser843-positive cells relative to 
DAPI-stained cells) obtained in four animals per group. One-way ANOVA (Post-hoc: Tukey’s 
range test): F(5,18)=8.967, p=0.0002. *p<0.05; **p<0.01, ***p<0.001. Scale bar: 100 µm. ns: 
not significant. 
 
Figure 2. 5-HT2A receptor-dependent phosphorylation of Ser843 elicited by LY379268 is 
mediated by casein kinase 1. A, HEK-293 cells co-expressing rat Flag-tagged mGlu2 and 
HA-tagged 5-HT2A receptors were pre-incubated with either vehicle or the CK1 inhibitor 
(D4476, 10 µM) or the PKA inhibitor (KT5720, 1 µM) for 60 min and then challenged with 
vehicle or LY379268 (LY37, 1 µM) for 15 min. B, HEK-293 cells co-expressing Flag-tagged 
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rat mGlu2 and HA-tagged 5-HT2A receptors were transfected with either control or CK1ε 
siRNA and challenged for 15 min with vehicle or LY379268 (LY37, 1 µM). Phosphorylation of 
mGlu2 receptor at Ser843 was assessed by sequential immunoblotting with the anti-phospho-
Ser843-mGlu2 receptor antibody and the anti-Flag antibody. Representative blots of three 
independent experiments performed on different sets of cultured cells are illustrated. The 
histograms show the means ± SEM of the anti-phospho-Ser843 mGlu2 receptor 
immunoreactive signal relative to Flag immunoreactive signal (expressed in arbitrary units, 
a.u.) obtained in the three experiments. One-way ANOVA (Post-hoc: Tukey’s range test): A, 
F(5,12)=10.23, p=0.0005. B, F(3,8)=8.114, p=0.0082. *p<0.05, **p<0.01 vs. corresponding 
vehicles. ns: not significant. 
 
Figure 3. Potentiation of mGlu2 receptor-operated Gi/o signaling elicited by 5-HT2A 
receptor expression depends on Ser843 phosphorylation. A, Schematic overview of N-
type calcium channel inhibition elicited upon activation of Gi/o-coupled receptors. B, Left 
panel: representative current traces obtained in response to vehicle (open circles) or 1 µM 
LY379268 (filled circles) in HEK-293 cells expressing Flag-tagged wild type mGlu2 receptor 
alone or in combination with HA-tagged 5-HT2A receptor. Right panel: HEK-293 cells, 
transiently expressing Flag-tagged wild type mGlu2 receptor alone or in combination with 
HA-tagged 5-HT2A receptor, were exposed to increasing concentrations of LY379268. Each 
point represents the means ± SEM of percentage of N-type calcium channel current 
inhibition measured in 10 cells from three different sets of cultured cells. C, Left panel: cells, 
expressing Flag-tagged mGlu2 receptor alone or co-expressing HA-tagged 5-HT2A receptor 
and either wild type or S843A or S843D Flag-tagged mGlu2 receptor, were exposed to 1 µM 
LY379268. Right panel: HEK-293 cells, expressing Flag-tagged mGlu2 receptor alone or co-
expressing HA-tagged 5-HT2A receptor and either wild type or S843D mGlu2 receptor, were 
treated with vehicle or D4476 (10 µM, delivered via the patch pipette 5 min before the 
LY379268 challenge). Representative traces of N-type calcium channel currents in 
conditions not depicted in B are illustrated. Histograms represent the means ± SEM of N-
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type calcium channel current inhibition induced by LY379268 in 10 cells from three 
independent cultures. One-way ANOVA (Post-hoc: Tukey’s range test): F(3,36)=16.94, 
p<0.0001 ; F(5,54)=17.15, p<0.0001 in left and right panels, respectively. ***p<0.001.  
 
Figure 4. 5-HT2A receptor stimulation promotes phosphorylation of mGlu2 at Ser843 in 
HEK-293 cells and mouse prefrontal cortex. A, HEK-293 cells co-expressing Flag-tagged 
mGlu2 receptor and HA-tagged 5-HT2A receptor were exposed to vehicle or 5-HT (1 µM, 15 
min) in the absence or presence of M100907 (100 nM). B, Cells were exposed to either 
vehicle or 5-HT (1 µM), or DOI (10 µM) or lisuride (10 µM) in the absence or presence of 
LY379268 (1 µM) for 15 min. Phosphorylation of mGlu2 receptor at Ser843 was assessed by 
sequential immunoblotting with the anti-phospho-Ser843-mGlu2 receptor antibody and the 
anti-Flag antibody. In A and B, representative blots of three independent experiments 
performed on different sets of cultured cells are illustrated. The histograms show the means 
± SEM of anti-phospho-Ser843 mGlu2 receptor immunoreactive signal relative to Flag 
immunoreactive signal (expressed in arbitrary units) obtained in the three experiments. A, 
One-way ANOVA (Post-hoc: Tukey’s range test): F(2,6)=16.63, p<0.0036. B, One-way 
ANOVA (Post-hoc: Dunnett’s range test): F(6,14)=7.779, p<0.0008. *p<0.05; **p<0.01; 
***p<0,001 vs. Vehicle. § p<0.05 vs. 5-HT. C, Wild type mice were injected with either 
vehicle or DOI (10 mg/kg, i.p) or lisuride (10 mg/kg, i.p). mGlu2-/- mice were injected with DOI 
(10 mg/kg, i.p). M100907 (5 mg/kg, i.p.) was injected 15 min before vehicle/DOI 
administration. Representative images showing phospho-Ser843-mGlu2 immunofluorescent 
staining in prefrontal cortex are illustrated. The histogram shows the mean ± SEM of values 
(expressed in % of anti-phospho-Ser843-positive cells relative to DAPI-stained cells) obtained 
in four animals per group. One-way ANOVA (Post-hoc: Tukey’s range test): F(4,15)=33.62, 
p<0.0001. ***p<0.001. Scale bar: 100 µm.  
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Figure 5. Reciprocal influence of mGlu2 and 5-HT2A receptor stimulation upon Gi/o 
signaling depends on Ser843 phosphorylation. A, HEK-293 cells co-expressing Flag-
tagged mGlu2 receptor and HA-tagged 5-HT2A receptor were exposed to vehicle or 5-HT (1 
µM), alone or in combination with LY341495 (10 µM), or to LY341495 alone (10 µM) for 15 
min. B, HEK-293 cells co-expressing Flag-tagged mGlu2 receptor and HA-tagged 5-HT2A 
receptor were exposed for 15 min to vehicle or LY379268 (10 nM), in the absence or 
presence of M100907 (100 nM). In A and B, mGlu2 receptor phosphorylation was analyzed 
by sequential immunoblotting with the anti-phospho-Ser843 antibody and the anti-Flag 
antibody. Representative blots of three independent experiments performed on different sets 
of cultured cells are illustrated. The histograms show the means ± SEM of the anti-phospho-
Ser843 mGlu2 receptor immunoreactive signal relative to Flag immunoreactive signal 
(expressed in arbitrary units, a.u.) obtained in the three experiments. One-way ANOVA 
(Post-hoc: Tukey’s range test): F(3,8)=22.49, p=0.0003 and F(3,8)=28.97, p=0.0001 in A 
and B, respectively. **p<0.01, ***p<0.001. C, Mice were injected with either DOI (10 mg/kg, 
i.p), LY379268 (10 mg/kg, i.p). M100907 (5 mg/kg, i.p.) and LY341495 (3 mg/kg, i.p.) were 
injected 15 min before vehicle/LY379268/DOI administration. Representative images 
showing phospho-Ser843-mGlu2 immunofluorescent staining in prefrontal cortex are 
illustrated. The histogram shows the mean ± SEM of values (expressed in % of anti-
phospho-Ser843-positive cells relative to DAPI-stained cells) obtained in four animals per 
group. One-way ANOVA (Post-hoc: Tukey’s range test): F(5,18)=24.57, p<0.0001. 
***p<0.001. Scale bar: 100 µm. D, HEK-293 cells, transiently expressing 5-HT2A receptor 
alone or in combination with either wild type or S843A or S843D mGlu2 receptor, were exposed 
to 1 µM 5-HT. Representative traces of N-type calcium channel currents obtained after 
exposure to vehicle or 5-HT are shown. The histograms represent the means ± SEM of N-
type calcium channel current inhibition measured for each treatment in 10 cells originating 
from three independent cultures. One-way ANOVA (Post-hoc: Tukey’s range test): 
F(3,36)=13.45, p<0.0001. ***p<0.001. E, Left panels: HEK-293 cells co-expressing 5-HT2A 
and mGlu2 receptors were sequentially challenged with LY3792968 (10 nM), LY341495 (10 
µM) and LY3792968 + LY341495 or with 5-HT (1 µM), M100907 (100 nM) and 5-HT + 
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M100907. Right panels: cells were sequentially challenged with LY3792968, M100907 and 
LY3792968 + M100907 or with 5-HT, LY341495 and 5-HT + LY341495. Representative 
traces of N-type calcium channel currents obtained after 5-HT or LY3792968 challenges (in 
absence or presence of M100907 or LY341495) are illustrated. The histograms represent 
the means ± SEM of N-type calcium channel current inhibition measured for each condition 
in 10 cells originating from three independent cultures. Note that M100907 or LY341495 
alone did not alter the N-type calcium channel current. One-way ANOVA (Post-hoc: Tukey’s 
range test): F(3,36)=89.9, p<0.0001; F(3,36)=78.18, p<0.0001 in left and right panels, 
respectively. ***p<0.001. 
 
Modified sequence Species Start-end 
Experimental 
m/z (Th) 
Theoretical 
mass (Da) 
∆ mass 
(ppm) 
Mascot 
score 
Phosphorylation site occupancy index 
mGlu2 mGlu2 + 5-HT2A 
Vehicle LY37 Vehicle LY37 
REVVt718LR + Phospho (ST) Human 714-720 477,2515 951,4903 -5,40 23 0,059 ± 0.03 0,057 ± 0.03 0,028 ± 0.02 0,042 ± 0.02 
APTs833RFGs837AAAR + 2 Phospho (ST) Human 830-841 676,2813 1350,5482 -0,18 31 0,222 ± 0.10 0,237 ± 0.12 0,228 ± 0.10 0,276 ± 0.10 
AS843S844SLGQGSGSQFVPTVCNGR + Phospho (ST) Human 842-862 1088,476 2174,9416 -1,93 136 0,004 ± 0.001 0,010 ± 0.001 0,006 ± 0.0007 0,025 ± 0.004*** 
EVVDSTTSs871L + Phospho (ST) Human 863-872 559,2383 1116,4588 2,9 53 0,052 ± 0.02 0,041 ± 0.01 0,052 ± 0.01 0,047 ± 0.003 
As843ANLGQGSGSQFVPTVCNGR + Phospho (ST) Rat 842-862 1093,9878 2185,9576 1,57 60 0,040 ± 0.01 0,041 ± 0.01 0,032 ± 0.01 0,112 ± 0.02* 
 
Table 1. List of phosphorylated peptides identified from purified mGlu2 receptors by nano-LC-MS/MS. HEK-293 cells transiently expressing human or rat 
Flag-tagged mGlu2 receptor, with or without HA-tagged 5-HT2A receptor, were exposed to either Vehicle or LY379268 (1 µM, 15 min). Solubilized receptors were 
immunoprecipitated with the anti-Flag M2 antibody, resolved by SDS-PAGE and digested in-gel with trypsin. Peptides were analyzed by nano-LC-MS/MS using 
multistage activation on the neutral loss of phosphoric acid. MS/MS spectra were manually interpreted. For each peptide, the position of modified residue(s), the 
position in the protein sequence, experimental mass/charge, theoretical mass, mass deviation, Mascot score, and relative abundance compared with the non-
phosphorylated peptide (site occupancy index: maximal intensity observed in the phosphorylated peptide extracted ion chromatogram/sum of the maximal 
intensities observed in the phosphorylated and the non-phosphorylated peptide extracted ion chromatograms) are indicated. The data are the means of values 
calculated from three independent experiments performed on different sets of cultured cells. *p<0.05, *** p<0.001 vs. corresponding vehicles. 
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Supplementary Figure 1. Sequence coverage of human and rat mGlu2 receptors 
obtained by LC-MS/MS. The sequence covered by LC-MS/MS analysis is highlighted in 
red. Identified phosphorylated residues in human mGlu2 receptor (Thr718, Ser833, Ser837, 
Ser843/844, Ser871) and rat mGlu2 receptor (Ser843, Ser871) and their positions are highlighted in 
blue. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Identification and quantification of the REVVt718LR 
phosphorylated peptide by LC-MS. A, The MS/MS spectrum that yielded the highest 
Mascot score, matched b and y ions, peptide sequence and position of the phosphorylated 
residue in the full-length human mGlu2 receptor are illustrated. B, Representative extracted 
ion chromatograms of this peptide in cells expressing mGlu2 receptor alone or in 
combination with 5-HT2A receptor, and exposed to either vehicle or LY379268 (1 µM) for 15 
min. The histogram represents the means ± SEM of ion signal intensities of REVVt718LR 
phosphorylated peptide obtained in three independent experiments performed on 
independent cultures. One-way ANOVA (Post-hoc: Tukey’s range test): F(3,12)=0.3072, 
p=0.8197. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Identification and quantification of the APTs833RFGs837AAAR 
phosphorylated peptide by LC-MS. A, The MS/MS spectrum that yielded the highest 
Mascot score, matched b and y ions, peptide sequence and position of the phosphorylated 
residue in the full-length human mGlu2 receptor are illustrated. B, Representative extracted 
ion chromatograms of this peptide in cells expressing mGlu2 receptor alone or in 
combination with 5-HT2A receptor, and exposed to either vehicle or LY379268 (1 µM) for 15 
min. The histogram represents the means ± SEM of ion signal intensities of 
APTs833RFGs837AAAR phosphorylated peptide obtained in three independent experiments 
performed on independent cultures. One-way ANOVA (Post-hoc: Tukey’s range test): 
F(3,12)=0.05346, p=0.9829. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. Identification and quantification of the 
AS843S844SLGQGSGSQFVPTVCNGR phosphorylated peptide by LC-MS. The MS/MS 
spectrum that yielded the highest Mascot score, matched b and y ions, peptide sequence 
and position of the phosphorylated residue in the full-length human mGlu2 receptor are 
illustrated (top panel). The bottom panels show representative extracted ion chromatograms 
of the peptide in cells expressing mGlu2 receptor alone or in combination with 5-HT2A 
receptor, and exposed to either vehicle or LY379268 (1 µM) for 15 min. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5. Identification and quantification of the EVVDSTTSs871L 
phosphorylated peptide by LC-MS. A, The MS/MS spectrum that yielded the highest 
Mascot score, matched b and y ions, peptide sequence and position of the phosphorylated 
residue in the full-length human mGlu2 receptor are illustrated. B, Representative extracted 
ion chromatograms of this peptide in cells expressing mGlu2 receptor alone or in 
combination with 5-HT2A receptor, and exposed to either vehicle or LY379268 (1 µM) for 15 
min. The histogram represents the means ± SEM of ion signal intensities of EVVDSTTSs871L 
phosphorylated peptide obtained in three independent experiments performed on 
independent cultures. One-way ANOVA (Post-hoc: Tukey’s range test): F(3,12)=0.2874, 
p=0.8337. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6. LC-MS analysis of human mGlu2 receptor digested with 
chymotrypsin. A, The sequence covered by LC-MS/MS analysis after in-gel digestion of 
human mGlu2 receptor with chymotrypsin is highlighted in red. Identified phosphorylated 
residues and their positions in the protein sequence are highlighted in blue. B, The MS/MS 
spectrum of the GSAAARAS843S844SLGQGSGSQF phosphorylated peptide that yielded the 
highest Mascot score, matched b and y ions, peptide sequence and position of the possible 
phosphorylated residues in the full-length receptor are underlined. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7. Identification and quantification of the 
As843ANLGQGSGSQFVPTVCNGR phosphorylated peptide by LC-MS. The MS/MS 
spectrum that yielded the highest Mascot score, matched b and y ions, peptide sequence 
and position of the phosphorylated residue in the full-length rat mGlu2 receptor are illustrated 
(top panel). The bottom panels show representative extracted ion chromatograms of the 
As843ANLGQGSGSQFVPTVCNGR peptide in cells expressing mGlu2 receptor alone or in 
combination with 5-HT2A receptor and treated with either vehicle or LY379268 (1 µM) for 15 
min. 
  
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8. Identification of the As843ASLGQGSGSQFVPTVCNGR 
phosphorylated peptide in S844A mGlu2 receptor. The MS/MS spectrum that yielded the 
highest Mascot score, matched b and y ions, peptide sequence and position of the 
phosphorylated residue in the full-length human S844A mGlu2 receptor are illustrated.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 9. Validation of the anti-phospho-Ser843 mGlu2 receptor 
antibody by Western blotting. HEK-293 cells transiently expressing rat Flag-tagged mGlu2 
receptor alone or in combination with HA-tagged 5-HT2A receptor or co-expressing rat Flag-
tagged S843A mGlu2 receptor and HA-tagged 5-HT2A receptor were exposed to vehicle or 
LY379268 (LY37, 1 µM) for 15 min. mGlu2 receptor phosphorylation was analyzed by 
sequential immunoblotting with the antibody raised against the CAAPRAsANLGQG peptide 
and the anti-Flag antibody. Representative blots of three independent experiments 
performed on different sets of cultured cells are illustrated. The generated antibody provided 
an immunoreactive signal in Western blots from cells expressing Flag-tagged mGlu2 
receptors at a molecular weight corresponding to the signal obtained with the anti-Flag 
antibody. The histograms show the means ± SEM of the anti-phospho-Ser843 mGlu2 receptor 
immunoreactive signal relative to Flag immunoreactive signal (expressed in arbitrary units, 
a.u.) obtained in the three experiments. One-way ANOVA (Post-hoc: Tukey’s range test): 
F(5,12)=58.02, p<0.0001. ***p<0.001. nd: non-detectable. 
Supplementary Figure 10. Effects of increasing concentrations of LY379268 and 5-HT 
on Ser843 phosphorylation. A, HEK-293 cells co-expressing Flag-tagged mGlu2 receptor 
and HA-tagged 5-HT2A receptor were exposed to vehicle or increasing concentrations of 
LY379268 (LY37, 1 nM, 3 nM, 10 nM, 100 nM, 1 µM) for 15 min. B, Cells were exposed to 
vehicle or increasing concentrations of 5-HT (0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM) for 15 
min. Phosphorylation of mGlu2 receptor at Ser843 was assessed by immunoblotting with the 
anti-phospho-Ser843-mGlu2 receptor antibody and mGlu2 receptor expression by 
immunoblotting with the anti-Flag antibody. Representative blots of three independent 
experiments performed on different sets of cultured cells are illustrated. The histograms 
show the means ± SEM of the anti-phospho-Ser843 mGlu2 receptor immunoreactive signal 
relative to Flag immunoreactive signal (expressed in arbitrary units, a.u.). One-way ANOVA 
(Post-hoc: Dunnett’s range test): A, F(5,12)=9.884, p=0.0005. B, F(5,12)=20.46, p<0.0001. 
*p<0.05 vs. corresponding vehicle conditions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 11. Basal mGlu2 receptor Ser843 phosphorylation level does not 
depend on 5-HT2A receptor expression level. HEK-293 cells co-expressing rat Flag-
tagged mGlu2 receptor and increasing amounts of HA-tagged 5-HT2A receptor were 
challenged with vehicle or LY379268 for 15 min. Phosphorylation of mGlu2 receptor at Ser843 
was assessed by sequential immunoblotting with the anti-phospho-Ser843-mGlu2 receptor 
antibody and with the anti-Flag antibody. Representative blots of three independent 
experiments performed on different sets of cultured cells are illustrated. The histograms 
show the means ± SEM of the anti-phospho-Ser843 mGlu2 receptor immunoreactive signal 
relative to Flag immunoreactive signal (expressed in arbitrary units, a.u.). One-way ANOVA 
(Post-hoc: Tukey’s range test): F(6,14)=0.4493, p=0.8338.    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 12. LY379268-elicited mGlu2 receptor phosphorylation at Ser843 
in cells co-expressing 5-HT2A receptor is prevented by the mGlu2 receptor antagonist 
LY341495. HEK-293 cells transiently expressing rat Flag-tagged mGlu2 receptor alone or in 
combination with HA-tagged 5-HT2A receptor were exposed to vehicle or LY379268 (LY37, 
10 nM), in absence or presence of LY341495 (LY34, 10 µM) for 15 min. mGlu2 receptor 
phosphorylation was analyzed by sequential immunoblotting with the anti-phospho-Ser843 
antibody and the anti-Flag antibody. Representative blots of three independent experiments 
performed on different sets of cultured cells are illustrated. The histograms show the means 
± SEM of the anti-phospho-Ser843 mGlu2 receptor immunoreactive signal relative to Flag 
immunoreactive signal (expressed in arbitrary units, a.u.) obtained in the three experiments. 
One-way ANOVA (Post-hoc: Tukey’s range test): F(5,12)=8.407, p=0.0013. *p<0.05; 
**p<0.01. 
  
 
 
 
 
 
 
 
 
 
Supplementary Figure 13. Western blot analysis of rat and human mGlu2 receptor 
phosphorylation at Ser843.  HEK-293 cells co-expressing HA-tagged 5-HT2A receptor and 
either rat or human Flag-tagged mGlu2 receptor were exposed to vehicle or LY379268 
(LY37, 1 µM) for 15 min. The phosphorylation of rat and human mGlu2 receptor at Ser843 
was analyzed by Western blotting using the newly generated anti-phospho-Ser843 mGlu2 
receptor antibody. Note that LY379268 treatment increased the immunoreactive signal of 
both rat and human orthologs, but the signal intensity was much higher for the rat receptor.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 14. LY379268-induced Ser843 phosphorylation in cells 
expressing mGlu2 receptor alone is not mediated by casein kinase 1. HEK-293 cells 
expressing rat Flag-tagged mGlu2 alone were pre-incubated with either vehicle or the CK1 
inhibitor (D4476, 10 µM) for 60 min and then challenged with vehicle or LY379268 (LY37, 1 
µM) for 15 min. Phosphorylation of mGlu2 receptor at Ser843 was assessed by sequential 
immunoblotting with the anti-phospho-Ser843-mGlu2 receptor antibody and the anti-Flag 
antibody. Representative blots of three independent experiments performed on different sets 
of cultured cells are illustrated. The histograms show the means ± SEM of the anti-phospho-
Ser843 mGlu2 receptor immunoreactive signal relative to Flag immunoreactive signal 
(expressed in arbitrary units, a.u.) obtained in the three experiments. One-way ANOVA 
(Post-hoc: Tukey’s range test): F(3,8)=0.1738, p=0.9112 
  
 
 
 
 
 
 
 
 
 
Supplementary Figure 15. Silencing casein kinase 1ε (CK1ε) expression in HEK-293 
cells by RNA interference. HEK-293 cells co-expressing rat Flag-tagged mGlu2 and HA-
tagged 5-HT2A receptors were transfected with either control or CK1ε siRNA and challenged 
with vehicle or LY379268 (LY37, 1 µM) for 15 min. CK1ε protein expression was assessed 
by sequential immunoblotting with the anti-CK1ε antibody and the anti-β-actin antibody. 
Representative blots of three independent experiments performed on different sets of 
cultured cells are illustrated. The histograms show the means ± SEM (expressed in arbitrary 
units, a.u.) of the anti-CK1ε immunoreactive signal relative to β-actin immunoreactive signal 
obtained in the three experiments. One-way ANOVA (Post-hoc: Tukey’s range test): F(3, 
8)=230, p<0.0001. *** p<0.001 vs. corresponding condition in presence of control siRNA. 
 Supplementary Figure 16. Role of Gi/o and Gq proteins in the phosphorylation of 
mGlu2 receptor at Ser843. A, HEK-293 cells co-expressing rat Flag-tagged mGlu2 and HA-
tagged 5-HT2A receptors were pre-incubated with either vehicle or Pertussis toxin (PTX, 0.1 
µg/mL, 18 h) or FR900359 (1 µM, 2 h) and challenged with either vehicle or LY379268 
(LY37, 1 µM, 15 min). B, HEK-293 cells were challenged with either vehicle or 5-HT (1 µM, 
15 min). Phosphorylation of mGlu2 receptor at Ser843 was assessed by immunoblotting with 
the anti-phospho-Ser843-mGlu2 receptor antibody and mGlu2 receptor expression by 
immunoblotting with the anti-Flag antibody. Representative blots of three independent 
experiments performed on different sets of cultured cells are illustrated. The histograms 
show the means ± SEM of the anti-phospho-Ser843 mGlu2 receptor immunoreactive signal 
relative to Flag immunoreactive signal (expressed in arbitrary units, a.u.). One-way ANOVA 
(Post-hoc: Tukey’s range test): A, F(5,12)=14.82, p<0.0001. B, F(5,12)=17.37, p<0.0001. 
*p<0.05; **p<0.01 vs. corresponding vehicles.    
  
 
 
 
 
 
 
 
 
Supplementary Figure 17. Neither LY379268 nor 5-HT promote Ser843 phosphorylation 
in cells expressing Gq signaling-dead D120N 5-HT2A receptor. A, HEK-293 cells co-
expressing rat Flag-tagged mGlu2 in combination with HA-tagged wild type or D120N 5-HT2A 
receptor were treated with either vehicle or LY379268 (LY37, 1 µM) for 15 min. B, HEK-293 
cells were treated with either vehicle or 5-HT (1 µM) for 15 min. Phosphorylation of mGlu2 
receptor at Ser843 was assessed by immunoblotting with the anti-phospho-Ser843-mGlu2 
receptor antibody and mGlu2 receptor expression by immunoblotting with the anti-Flag 
antibody. Representative blots of three independent experiments performed on different sets 
of cultured cells are illustrated. The histograms show the means ± SEM of the anti-phospho-
Ser843 mGlu2 receptor immunoreactive signal relative to Flag immunoreactive signal 
(expressed in arbitrary units, a.u.). One-way ANOVA (Post-hoc: Tukey’s range test): A, 
F(3,8)=14.92, p=0.0012. B, F(3,8)=17.79, p=0.0007. *p<0.05; **p<0.01 vs. corresponding 
vehicles.    
  
 
 
 
 
 
 
 
 
Supplementary Figure 18. Ser843 phosphorylation does not affect cell surface 
expression of mGlu2 and 5-HT2A receptors. Quantification of cell surface expression of 
HA-tagged 5-HT2A receptors (A) and Flag-tagged mGlu2 receptors (B) was performed by 
ELISA in non-permeabilizing conditions using anti-HA and anti-Flag antibodies, respectively, 
in cells expressing 5-HT2A or wild type mGlu2 receptor alone or 5-HT2A receptor in 
combination with either wild type or S843A or S843D mGlu2 receptor. Data are the means ± 
SEM of values obtained in three independent experiments. One-way ANOVA (Post-hoc: 
Tukey’s range test): A, F(5.48)=12.97, p<0.0001; B, F(5.48)=23.64. p<0.0001. ***p<0.001 
vs. cells transfected with empty vectors (Mock). 
